Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-06

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this project is to study brain energy profile evolution at different stages of the Huntington disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dynamic Neuroimaging Biomarkers in Huntington's Disease

NCT02639871

Brain Neuroimaging Biomarkers in Huntington Disease

COMPLETED

Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression

NCT05808153

Huntington Disease

RECRUITING NA

[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.

NCT02061722

Huntington's Disease

COMPLETED EARLY_PHASE1

Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers

NCT02956148

Huntington's Disease

COMPLETED EARLY_PHASE1

Molecular and Functional Imaging in Monogenic PD.

NCT05518617

Parkinson Disease Nervous System Disorder Neurodegenerative Diseases +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

31-Phosphorus RMN Spectroscopy

Group Type OTHER

31-Phosphorus RMN Spectroscopy

Intervention Type OTHER

Volunteers

31-Phosphorus RMN Spectroscopy

Group Type OTHER

31-Phosphorus RMN Spectroscopy

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

31-Phosphorus RMN Spectroscopy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* UHDRS \< 50
* Age \> 18 years
* Ability to undergo MR scanning
* Covered by french social security

Exclusion Criteria

* Evidence of psychiatric disorder
* Attendant neurological disorder
* Contraindications to MRI (claustrophobia, metallic or material implants)
* Severe head injury
* Unable to understand the protocol
* Pregnancy
* Failure to give informed consent
* Unwillingness to be informed in case of abnormal MRI

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes